Monsanto signs option agreement to support biologicals platform
15:01 PM | January 13, 2014 | Rebecca Coons
Tekmira Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has signed an option agreement under which Monsanto may obtain a license to use Tekmira's...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.